Ani Pharmaceuticals (ANIP) Goodwill & Intangibles (2012 - 2026)

Ani Pharmaceuticals (ANIP) has 15 years of Goodwill & Intangibles data on file, last reported at $529.6 million in Q1 2026.

• For the quarter ending Q1 2026, Goodwill & Intangibles fell 11.6% year-over-year to $529.6 million; the trailing twelve-month figure through Mar 2026 stood at $529.6 million (down 11.6% YoY), and the FY2025 full-year result was $542.0 million, down 9.94% from the prior year.
• Goodwill & Intangibles slipped to $529.6 million in Q1 2026, from $542.0 million in the prior quarter.
• In the past five years, Goodwill & Intangibles ranged from a high of $630.3 million in Q3 2024 to a low of $32.5 million in Q2 2023.
• A 5-year average of $349.5 million and a median of $292.5 million in 2022 frame the typical range for Goodwill & Intangibles.
• Across the five-year window, Goodwill & Intangibles plunged 89.08% in 2023 and soared 549.73% in 2024, its largest moves.
• Tracing ANIP's Goodwill & Intangibles over 5 years: stood at $279.8 million in 2022, then slipped by 15.23% to $237.2 million in 2023, then jumped by 153.69% to $601.8 million in 2024, then retreated by 9.94% to $542.0 million in 2025, then declined by 2.28% to $529.6 million in 2026.
• Business Quant data shows ANIP's Goodwill & Intangibles at $529.6 million in Q1 2026, $542.0 million in Q4 2025, and $562.3 million in Q3 2025.